AU1403099A - Alpha-1a adrenergic receptor antagonists - Google Patents

Alpha-1a adrenergic receptor antagonists

Info

Publication number
AU1403099A
AU1403099A AU14030/99A AU1403099A AU1403099A AU 1403099 A AU1403099 A AU 1403099A AU 14030/99 A AU14030/99 A AU 14030/99A AU 1403099 A AU1403099 A AU 1403099A AU 1403099 A AU1403099 A AU 1403099A
Authority
AU
Australia
Prior art keywords
alpha
receptor antagonists
adrenergic receptor
adrenergic
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU14030/99A
Inventor
James Barrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807940.3A external-priority patent/GB9807940D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU1403099A publication Critical patent/AU1403099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
AU14030/99A 1997-11-14 1998-11-12 Alpha-1a adrenergic receptor antagonists Abandoned AU1403099A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US6599697P 1997-11-14 1997-11-14
US60065996 1997-11-14
US6648397P 1997-11-24 1997-11-24
US60066483 1997-11-24
GBGB9807940.3A GB9807940D0 (en) 1998-04-15 1998-04-15 Alpha-1a adrenergic receptor antagonists
GB9807940 1998-04-15
PCT/US1998/024148 WO1999025345A1 (en) 1997-11-14 1998-11-12 Alpha-1a adrenergic receptor antagonists

Publications (1)

Publication Number Publication Date
AU1403099A true AU1403099A (en) 1999-06-07

Family

ID=27269281

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14030/99A Abandoned AU1403099A (en) 1997-11-14 1998-11-12 Alpha-1a adrenergic receptor antagonists

Country Status (2)

Country Link
AU (1) AU1403099A (en)
WO (1) WO1999025345A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6207444B1 (en) 1997-08-05 2001-03-27 Merck & Co., Inc. Enzymatic process of making alpha 1a adrenergic receptor antagonists using protease
US6228870B1 (en) 1998-11-10 2001-05-08 Merck & Co., Inc. Oxazolidinones useful as alpha 1a adrenoceptor antagonists
US6319932B1 (en) 1998-11-10 2001-11-20 Merck & Co., Inc. Oxazolidinones useful as alpha 1A adrenoceptor antagonists
US6331541B1 (en) 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
JP2004506013A (en) * 2000-08-17 2004-02-26 メルク　エンド　カムパニー　インコーポレーテッド Cyclopentyl chemokine receptor activity modulator
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
KR102040007B1 (en) 2012-12-21 2019-11-05 길리애드 사이언시즈, 인코포레이티드 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
ES2645192T3 (en) 2013-07-12 2017-12-04 Gilead Sciences, Inc. Polycyclic carbamoylpyridone compounds and their use for the treatment of HIV infections
NO2865735T3 (en) 2013-07-12 2018-07-21
TWI677489B (en) 2014-06-20 2019-11-21 美商基利科學股份有限公司 Synthesis of polycyclic-carbamoylpyridone compounds
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (en) 2014-06-20 2018-06-23

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847379A (en) * 1987-11-30 1989-07-11 E. R. Squibb & Sons, Inc. 3,6-dihydro-1,5(2H)-pyrimidinecarboxylic acid esters
US5047406A (en) * 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
US5661163A (en) * 1995-06-07 1997-08-26 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists

Also Published As

Publication number Publication date
WO1999025345A1 (en) 1999-05-27

Similar Documents

Publication Publication Date Title
AU7692996A (en) Receptor antagonists
HK1029574A1 (en) 1-amino-alkylcyclohexane nmda receptor antagonists
AU8689798A (en) Integrin receptor antagonists
AU1345697A (en) Novel integrin receptor antagonists
AU3579897A (en) Fibrinogen receptor antagonists
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
AU1765695A (en) Non-peptidyl tachykinin receptor antagonists
HU9603525D0 (en) Vironectin receptor antagonists
AU2143295A (en) Neurokinin receptor antagonists
AU4746297A (en) Vitronectin receptor antagonists
AU6267198A (en) Amides as npy5 receptor antagonists
EP0822814A4 (en) ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
EP0998285A4 (en) ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
AU4698299A (en) 5-HT7 receptor antagonists
AU2242197A (en) Benzimidzolyl neuropeptide y receptor antagonists
AU8673198A (en) Il-8 receptor antagonists
AU1230795A (en) Adhesion receptor antagonists
EP0831823A4 (en) ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
EP0755392A4 (en) Alpha1c adrenergic receptor antagonists
AU1403099A (en) Alpha-1a adrenergic receptor antagonists
AU9185598A (en) Novel neuropeptide y receptor antagonists
EP1019052A4 (en) Alpha 1a adrenergic receptor antagonists
EP1023068A4 (en) ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
AU3661895A (en) Adhesion receptor antagonists
AU2180600A (en) Non-peptide nk1 receptors antagonists

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase